Dr Reddy’s Laboratories moved higher by 3% to Rs 2,380, gaining 9% during the week. The pharmaceutical company is the top weekly gainer among the S&P BSE Sensex stocks.
The company on Monday, December 11, 2017 announced that it has received Establishment Inspection Report (EIR) from the US drug regulator for its facility in Bachupally, Hyderabad following the audit in April.
“We have received EIR from the US Food and Drug Administration (USFDA) on December 11, 2017 as closure of audit, for formulations manufacturing plant-3 at Bachupally, Hyderabad,” Dr Reddy’s Laboratories said in a statement.
The above-referred
The company on Monday, December 11, 2017 announced that it has received Establishment Inspection Report (EIR) from the US drug regulator for its facility in Bachupally, Hyderabad following the audit in April.
“We have received EIR from the US Food and Drug Administration (USFDA) on December 11, 2017 as closure of audit, for formulations manufacturing plant-3 at Bachupally, Hyderabad,” Dr Reddy’s Laboratories said in a statement.
The above-referred